Obinutuzumab-based immunochemotherapy improves progression-free survival compared with rituximab-based immunochemotherapy in patients with previously untreated, advanced follicular lymphoma, new research suggests. Robert Marcus (King's College Hospital, London, UK) and colleagues randomly assigned patients with advanced follicular lymphoma (grades III–IV, or stage II with bulk disease) to undergo induction chemotherapy with obinutuzumab (n=601) or rituximab (n=601). Patients with a response received maintenance treatment for up to 2 years with the same antibody that they received in induction.

中文翻译：

---

一线奥比妥珠单抗治疗滤泡性淋巴瘤

新的研究表明，与以前基于利妥昔单抗的免疫化学疗法相比，基于奥比妥珠单抗的免疫化学疗法可改善无进展生存率。罗伯特·马库斯（罗伯特·马库斯，英国伦敦国王学院医院）及其同事将晚期滤泡性淋巴瘤（III–IV级或II期伴大块疾病）患者随机分配接受奥比妥珠单抗（n = 601）或利妥昔单抗（n = 601）进行诱导化疗）。有反应的患者使用诱导诱导的相同抗体接受长达2年的维持治疗。